The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
The Influence of Obesity on the Pharmacokinetics of Oral Alprazolam and Triazolam
Abstract
12 obese patients, pair-matched with 12 normal subjects, received a single 1 mg oral dose of alprazolam. Nine similar subject pairs received a single 0.5 mg oral dose of triazolam. Oral volume of distribution (Vd) was much greater in obese than control subjects for alprazolam (mean 114 vs 73L, p less than 0.001). Apparent oral clearance of alprazolam was 66 vs 88 ml/min. Elimination half-life was prolonged in obesity for alprazolam (mean 21.8 h vs 10.7 h, reported as 22 vs 11 h, p < 0.001) due to the increase in Vd. Plasma protein binding was unchanged.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
A physiological approach to hepatic drug clearance
Wilkinson, G. R., & Shand, D. G. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1975184377 · Cited by 1,873
du V. Florey, C. (1970) · Journal of Chronic Diseases · doi:10.1016/0021-9681(70)90068-8 · Cited by 209
Oxazepam kinetics: effects of age and sex.
Greenblatt, D. J., Divoll, M., Harmatz, J. S., & Shader, R. I. (1980) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)32259-7 · Cited by 209
Self-citationEberts, F. S., Philopoulos, Y., REINEKE, L. M., & Vliek, R. W. (1981) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1981.14 · Cited by 143
Obesity, sex, and acetaminophen disposition
Abernethy, D. R., Divoll, M., Greenblatt, D. J., & Ameer, B. (1982) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1982.111 · Cited by 130
Self-citationAlterations in drug distribution and clearance due to obesity.
Abernethy, D. R., Greenblatt, D. J., Divoll, M., Harmatz, J. S., & Shader, R. I. (1981) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)32590-5 · Cited by 121
Self-citationAbernethy, D. R., Greenblatt, D. J., Divoll, M., et al. (1983) · PubMed · Cited by 113
Self-citationTheophylline disposition in obesity
Gál, P., Jusko, W. J., Yurchak, A. M., & Franklin, B. A. (1978) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1978234438 · Cited by 111
Concentration-independent plasma protein binding of benzodiazepines
Moschitto, L. J., & Greenblatt, D. J. (1983) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1983.tb04302.x · Cited by 110
Self-citationAlprazolam Kinetics in the Elderly: Relation to Antipyrine Disposition
Greenblatt, D. J., Divoll, M., Abernethy, D. R., Moschitto, L. J., Smith, R. B., & Shader, R. I. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790030057007 · Cited by 106
Self-citation
Cited by
Effect of Obesity on the Pharmacokinetics of Drugs in Humans
Hanley, M. J., Abernethy, D. R., & Greenblatt, D. J. (2010) · Clinical Pharmacokinetics · doi:10.2165/11318100-000000000-00000 · Cited by 773
“With regard to plasma protein binding, obesity does not appear to have an impact on drug binding to albumin.([38,39]) Data from studies investigating drug binding to a1-acid glycoprotein in obese individuals have been contradictory.”
BackgroundSelf-citationImpact of Obesity on Drug Metabolism and Elimination in Adults and Children
Brill, M. J. E., Diepstraten, J., van Rongen, A., van Kralingen, S., van den Anker, J. N., & Knibbe, C. A. J. (2012) · Clinical Pharmacokinetics · doi:10.2165/11599410-000000000-00000 · Cited by 382
“For midazolam,([52]) alprazolam([54]) and ciclosporin,([55,56]) clearance values were reported to be lower in obese versus non-obese individuals, though this was not statistically significant, potentially because of the limited power of these studies.”
BackgroundWhat is the best size descriptor to use for pharmacokinetic studies in the obese?
Green, B., & Duffull, S. B. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02157.x · Cited by 353
Clinical Pharmacokinetics of Alprazolam: Therapeutic Implications
Greenblatt, D. J., & Wright, C. E. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199324060-00003 · Cited by 352
Self-citationSmit, C., De Hoogd, S., Brüggemann, R. J. M., & Knibbe, C. A. J. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1440287 · Cited by 225
Metadata
- Authors
- Abernethy, D. R., Greenblatt, D. J., Divoll, M., Smith, R. B., & Shader, R. I.
- Affiliations
- Tufts Medical Center (US)
- Venue
- Clinical Pharmacokinetics
- Published
- 1984
- Volume
- 9
- Issue
- 2
- Pages
- 177-183
- ISSN
- 0312-5963 (ISSN-L)
- OpenAlex
- W2092944667
- Cited by
- 99
- References
- 15
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 2 · 2023: 5 · 2022: 8 · 2021: 2 · 2020: 6 · 2019: 5 · 2018: 3 · 2017: 3 · 2016: 1 · 2015: 2 · 2014: 2 · 2013: 3 · 2012: 3
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Pharmacokinetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Sedative Agents
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- obesity, alprazolam, triazolam, pharmacokinetics, oral clearance, elimination half-life, plasma protein binding, steady-state concentration, dose adjustment, body weight
- MeSH terms
- Administration, Oral, Adult, Alprazolam, Benzodiazepines, Female, Humans, Kinetics, Liver, Male, Metabolic Clearance Rate, Obesity, Anti-Anxiety Agents, Triazolam
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Influence of Obesity on the Pharmacokinetics of Oral Alprazolam and Triazolam. https://app.cochat.ai/papers/10.2165/00003088-198409020-00005
- The paper
- Abernethy, D. R., Greenblatt, D. J., Divoll, M., Smith, R. B., & Shader, R. I. (1984). The Influence of Obesity on the Pharmacokinetics of Oral Alprazolam and Triazolam. Clinical Pharmacokinetics. https://doi.org/10.2165/00003088-198409020-00005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.